Thoracic Medical Oncologist at Johns Hopkins at Sibley @hopkinskimmel @sibleyonline
Baltimore, MD
Joined February 2013
- Tweets438
- Following491
- Followers979
- Likes1.9K
Susan Combs Scott, MD retweeted
Join us in Washington, DC tomorrow, Saturday, October 10 for #DCLung26 - a 1-day, comprehensive, @IASLC endorsed, multidisciplinary, discussion-based lung cancer CME update!
On-site registration available and join us afterwards for our inaugural gala!
medstarhealth.org/dclung
Susan Combs Scott, MD retweeted
Another reminder @JCOPO_ASCO - early NGS testing in NSCLC before 1L therapy improves outcomes. This retrospective Flatiron study from Drs. @SusanScottMD @benlevylungdoc in > 13k pts showed upfront NGS led to more use of targeted therapy & longer OS.
ascopubs.org/doi/10.1200/PO-…
Susan Combs Scott, MD retweeted
My first #lead2026 was one for the books!
- cancer updates
- AI + medicine
- mentorship
-advocacy
- negotiation
- watched @rachnatshroff beautiful acceptance speech -woman oncologist of the yr
We laughed + cried and came out stronger than ever! Cheers to this wolf pack!
Susan Combs Scott, MD retweeted
IDEO Xchange: Which data from WCLC26 are you most looking forward to seeing?
25%1L T-DXd in HER2m
12%New data in EGFR exon20
4%Zidesamtinib in 1L
58%B7-H3 ADCs in SCLC
24 votes • Final resultsEvaluation of progression-free survival as a surrogate endpoint for overall survival in small cell lung cancer: a systematic review - PubMed pubmed.ncbi.nlm.nih.gov/4115…
Susan Combs Scott, MD retweeted
IDEO Xchange: What is the single biggest unanswered question regarding future sequencing in 2L+ EGFRm mNSCLC?
35%Best order
22%Resistance mechanisms
13%Combination strategies
30%Patient selection
23 votes • Final results Susan Combs Scott, MD retweeted
IDEO Xchange: Which statement best reflects your current experience with the eye exam requirement for Dato-DXd?
31%Easy to integrate
38%Resource intensive
25%Challenging in some pts
6%Major burden
16 votes • Final results Susan Combs Scott, MD retweeted
🔴 LIVE tonight from Seoul: IDEO Xchange at #WCLC26! Join us right here on X for real-time polling as our experts dive into EGFRm mNSCLC (sequencing, Dato-DXd, future landscape), targeted therapy in early-stage & RAS, and breaking WCLC data.
Vote along with our experts:
@sands_jacob (Chair) @JuliaRotow @NarjustFlorezMD @VamsiVelcheti @ChristineBestv1 @DasMillie11 @ElaineShumMD @Latinamd Lyudmila Bazhenova @ChristianRolfo @maryjofidlerMD @SusanScottMD Siddhartha Devarakonda
#LungCancer
Susan Combs Scott, MD retweeted
Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a one-day, comprehensive, multidisciplinary, discussion-based lung cancer CME update! We will be discussing first-line EGFR NSCLC options with Dr. @SusanScottMD. Be sure to join us!
medstarhealth.org/dclung
Looking forward to another great DC Lung! #dclung26
Join us for #DCLung26 in Washington, DC on Saturday, October 10 - a packed CME event of discussion-based lung cancer updates you can't miss! Dr. @SusanScottMD returns to present the latest on the ever-evolving field of EGFRm NSCLC. Sign up today!
medstarhealth.org/dclung
Susan Combs Scott, MD retweeted
A heartfelt thank you to all of the faculty, sponsors, and attendees for a successful #TexasLung26. We hope to see everyone at #TexasLung27 - April 8-10, 2027 at Austin City Limits for the 5th annual @TLCconference! Save the date!
Susan Combs Scott, MD retweeted
Kicking off day 2 #Texaslung26 with these powerhouse @WomeninOnc @NarjustFlorezMD @JuliaRotow @SusanScottMD @LeXiuning @KMilehamMD
Biggest take 🏠:
- there is a role for consolidation in stage4
- proactive tox management
- focus on LMD
-we need to celebrate all wins
Susan Combs Scott, MD retweeted
Our first session is about to begin! Join Dr. @riess_md at 8:30 AM for expert insights on Advanced NSCLC: EGFR, featuring Drs. @SusanScottMD, @JuliaRotow, @ZPiotrowskaMD, Christina Baik, @chulkimMD, @LeXiuning, @jeffyoriomd at #TexasLung26 utm.rocks/tlcagenda?utm_sour…
Susan Combs Scott, MD retweeted
@SusanScottMD breaks down frontline management of EGFR+ mNSCLC.
For many (though not all) patients, upfront combination “intensification” strategies are becoming the new default.
#TexasLung26
Susan Combs Scott, MD retweeted
EGFR session kicking off with presentations by @SusanScottMD, @JuliaRotow, and @ZPiotrowskaMD ! @TLCconference #TexasLung26
Susan Combs Scott, MD retweeted
🔥GAME-CHANGER in 1L EGFR+ #NSCLC 🫁
#MARIPOSA trial: Amivantamab + Lazertinib delivers ~1-YEAR mOS benefit 🚀
✅SubQ Amivantamab ⬇️ infusion reactions + visit burden! 💉✨
@lungoncdoc @FawziAbuRous @JuliaRotow
@SusanScottMD #lcsm #OncTwitter
Ep. 1
oncupdates.com/video-podcast…
Susan Combs Scott, MD retweeted
🚨Ep. 2 OUT!: Proactive Toxicity Mgmt & CNS Control in #EGFR-Mutant #NSCLC 🧠
👉COCOON regimen ⬇️ grade ≥2 skin toxicity
👉MARIPOSA: 36% vs 18% 3-yr intracranial PFS vs osimertinib
#lcsm #OncTwitter @lungoncdoc @FawziAbuRous @JuliaRotow @SusanScottMD
oncupdates.com/video-podcast…
Susan Combs Scott, MD retweeted
🚨 Ep. 3 OUT NOW! Time Toxicity, CNS Risk & Sequencing Strategy in #EGFRMutant #NSCLC 🧠🫁
👉 MARIPOSA CNS data
👉SubQ amivantamab
⏰Time Toxicity
#lcsm #OncTwitter #Oncology #FOAMed @lungoncdoc @FawziAbuRous @JuliaRotow @SusanScottMD
🎙️Watch full 🗣️👇
oncupdates.com/video-podcast…
Susan Combs Scott, MD retweeted
Day 2 of Winter Lung is officially underway ❄️🫁
No arctic storm in Florida
@SusanScottMD & @JuliaRotow are kicking things off with The EGFR Crossfire: Monotherapy, Intensification, and Beyond
What’s your 1L EGFR choice? ami/laz vs osi/chemo vs osi mono 👇
@gotoPER #WLC26